Comparison of fasting plasma glucose and haemoglobin A1c point-of-care tests in screening for diabetes and abnormal glucose regulation in a rural low income setting

Diabetes Research and Clinical Practice

Volumn 104, Issue 1, 2014, Pages 112-120

  Mayega, Roy William ^a,b   Guwatudde, David ^a   Makumbi, Fredrick Edward ^a   Nakwagala, Frederick Nelson ^c   Peterson, Stefan ^a,b,d   Tomson, Göran ^b   Östenson, Claes Göran ^b  

^a MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MULAGO NATIONAL REFERRAL HOSPITAL   (Uganda)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Abnormal glucose regulation; Diabetes; Early detection; Fasting plasma glucose; Percentage agreement

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PRE-HEMOGLOBIN A, GLYCOSYLATED; PROTEIN PRECURSOR;

ABNORMAL GLUCOSE REGULATION; ADULT; AFRICA; ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BODY MASS; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOMETER; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INTERMETHOD COMPARISON; MALE; OBESITY; PREVALENCE; RISK FACTOR; RURAL POPULATION; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; POVERTY; PREDIABETIC STATE; UGANDA;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; POVERTY; PREDIABETIC STATE; PREVALENCE; PROTEIN PRECURSORS; RISK FACTORS; RURAL POPULATION; UGANDA;

EID: 84898541247     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.030     Document Type: Article

References (44)

1. Anand S.S., Razak F., Vuksan V., Gerstein H.C., Malmberg K., Yi Q., et al. Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care 2003, 26:290-296.
2. Waugh N., Scotland G., McNamee P., Gillett M., Brennan A., Goyder E., et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007, 11(17):1-125.
3. WHO Package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings 2010, WHO, Geneva.
4. ADA Standards of medical care in diabetes-2013. Diabetes Care 2013, 36:S11-S66. 10.2337/dc2313-S2011.
5. WHO/IDF Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation 2006.
6. Lyon A.W., Larsen E.T., Edwards A.L. The impact of new guidelines for glucose tolerance testing on clinical practice and laboratory services. CMAJ 2004, 171:1067-1069.
7. Herman W.H., Fajans S.S. Hemoglobin A1c for the diagnosis of diabetes: practical considerations. Pol Arch Med Wewn 2010, 120:37-40.
8. Wilson S.E., Lipscombe L.L., Rosella L.C., Manuel D.G. Trends in laboratory testing for diabetes in Ontario, Canada 1995-2005: a population-based study. BMC Health Serv Res 2009, 9:41.
9. Kumar P.R., Bhansali A., Ravikiran M., Bhansali S., Dutta P., Thakur J.S., et al. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. J Clin Endocrinol Metab 2010, 95:2832-2835.
10. 1C) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011, 93:299-309.
11. Jimeno Mollet J., Molist Brunet N., Franch Nadal J., Morato Griera J., Otzet Gramunt I., Pons Barro P. Diagnosing type 2 diabetes mellitus: in primary care, fasting plasma glucose and glycosylated haemoglobin do the job. Aten Primaria 2004, 34:222-228.
12. Unnikrishnan R., Mohan V. Challenges in estimation of glycated hemoglobin in India. Diabetes Technol Ther 2013, 10:897-899.
13. Hu Y., Liu W., Chen Y., Zhang M., Wang L., Zhou H., et al. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 2010, 47:231-236.
14. 1C) for postprandial hyperglycemia was equivalent to that of fasting blood glucose. J Clin Epidemiol 2005, 58:1052-1057.
15. Maher D., Sekajugo J. Research on health transition in Africa: time for action. Health Res Policy Syst 2011, 9:5.
16. Uganda MoH Health sector strategic plan III 2010/11-2014/15 2010, Uganda Ministry of Health, Kampala, Uganda.
17. Masaba J.P.M., Baingana S., Odiit A., Nalukenge K.L.O. Guidelines for non-communicable diseases at District level Official Website of the Ministry of Health, Republic of Uganda 1998, Uganda Ministry of Health.
18. Mayega R.W., Makumbi F., Rutebemberwa E., Peterson S., Ostenson C.G., Tomson G., et al. Modifiable socio-behavioural factors associated with overweight and hypertension among persons aged 35 to 60 years in eastern Uganda. PLoS ONE 2012, 7:e47632. 10.1371/journal.pone.0047632.
19. Fleiss J., Tytun A., Ury H. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 1980, 36:343-346.
20. Maher D., Waswa L., Baisley K., Karabarinde A., Unwin N., Grosskurth H., et al. Distribution of hyperglycaemia and related cardiovascular disease risk factors in low-income countries: a cross-sectional population-based survey in rural Uganda. Int J Epidemiol 2011, 40:160-171.
21. Whitworth J.A. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21:1983-1992.
22. Little R.R. Analysis: point-of-care testing for glycated hemoglobin (GHB). Diabetes Technol Ther 2005, 7:913-915.
23. Wood J.R., Kaminski B.M., Kollman C., Beck R.W., Hall C.A., et al. Accuracy and precision of the Axis-Shield Afinion hemoglobin A1c measurement device. J Diabetes Sci Technol 2012, 6:380-386.
24. Lenters-Westra E., Slingerland R.J. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010, 56:44-52.
25. Nazir A., Papita R., Anbalagan V.P., Anjana R.M., Deepa M., Mohan V. Prevalence of diabetes in Asian Indians based on glycated hemoglobin and fasting and 2-H post-load (75-g) plasma glucose (CURES-120). Diabetes Technol Ther 2012, 14(8):665-668. 10.1089/dia.2012.0059.
26. Schottker B., Raum E., Rothenbacher D., Muller H., Brenner H. Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur J Epidemiol 2011, 26:779-787.
27. Mann D.M., Carson A.P., Shimbo D., Fonseca V., Fox C.S., Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care 2010, 33:2190-2195.
28. Zhou X., Pang Z., Gao W., Wang S., Zhang L., Ning F., et al. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an Oral Glucose Tolerance Test in Qingdao, China. Diabetes Care 2010, 33:545-550.
29. Pinelli N.R., Jantz A.S., Martin E.T., Jaber L.A. Sensitivity and specificity of glycated hemoglobin as a diagnostic test for diabetes and prediabetes in Arabs. J Clin Endocrinol Metab 2011, 96.
30. Selvin E., Steffes M.W., Ballantyne C.M., Hoogeveen R.C., Coresh J., Brancati F.L. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011, 154:303-309. 10.7326/0003-4819-154-5-201103010-00004.
31. Ziemer D.C., Kolm P., Weintraub W.S., Vaccarino V., Rhee M.K., Twombly J.G. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010, 152:770-777. 10.7326/0003-4819-152-12-201006150-00004.
32. Kim K.S., Kim S.K., Lee Y.K., Park S.W., Cho Y.W. Diagnostic value of glycated haemoglobin HbA(1c) for the early detection of diabetes in high-risk subjects. Diabet Med 2008, 25:997-1000.
33. Bennett C.M., Guo M., Dharmage S.C. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 2007, 24:333-343.
34. 1C and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012, 97.
35. Boltri J.M., Okosun I.S., Davis-Smith M., Vogel R.L. Hemoglobin A1c levels in diagnosed and undiagnosed black, Hispanic, and white persons with diabetes: results from NHANES 1999-2000. Ethn Dis 2005, 15:562-567.
36. Lorenzo C., Wagenknecht L.E., Hanley A.J., Rewers M.J., Karter A.J., Haffner S.M. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010, 33:2104-2109.
37. Mohan V., Vijayachandrika V., Gokulakrishnan K., Anjana R.M., Ganesan A., Weber M.B. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010, 33(3):515-519.
38. 1C, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. J Intern Med 2006, 260:263-271.
39. 1C for the diagnosis of diabetes mellitus in a developing country. A position article. Arch Med Res 2010, 41:302-308.
40. Mostafa S.A., Davies M.J., Webb D., Gray L.J., Srinivasan B.T., Jarvis J., et al. The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting type 2 diabetes mellitus. Diabet Med 2010, 27:762-769.
41. Abegunde D.O., Shengelia B., Luyten A., Cameron A., Celletti F., Nishtar S., et al. Can non-physician health-care workers assess and manage cardiovascular risk in primary care?. Bull World Health Organ 2007, 85:432-440.
42. Beaglehole R., Epping-Jordan J., Patel V., Chopra M., Ebrahim S., Kidd M., et al. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet 2008, 372:940-949.
43. Bischoff A., Ekoe T.F., Perone N., Slama S., Loutan L. Chronic disease management in sub-Saharan Africa: whose business is it?. Int J Environ Res Public Health 2009, 6(8):2258-2270.
44. WHO Everybody business: strengthening health systems to improve health outcomes: WHO's framework for action 2007, WHO, Geneva, Switzerland.